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Abstract
Amyloid-like plaques are characteristic lesions defining the neuropathology of Alzheimer’s disease (AD). The size and
density of these plaques are closely associated with cognitive decline. To combat this disease, the few therapies that are
available rely on drugs that increase neurotransmission; however, this approach has had limited success as it has simply
slowed an imminent decline and failed to target the root cause of AD. Amyloid-like deposits result from aggregation of the
Ab peptide, and thus, reducing amyloid burden by preventing Ab aggregation represents an attractive approach to improve
the therapeutic arsenal for AD. Recent studies have shown that the natural product curcumin is capable of crossing the
blood-brain barrier in the CNS in sufficient quantities so as to reduce amyloid plaque burden. Based upon this bioactivity,
we hypothesized that curcumin presents molecular features that make it an excellent lead compound for the development
of more effective inhibitors of Ab aggregation. To explore this hypothesis, we screened a library of curcumin analogs and
identified structural features that contribute to the anti-oligomerization activity of curcumin and its analogs. First, at least
one enone group in the spacer between aryl rings is necessary for measureable anti-Ab aggregation activity. Second, an
unsaturated carbon spacer between aryl rings is essential for inhibitory activity, as none of the saturated carbon spacers
showed any margin of improvement over that of native curcumin. Third, methoxyl and hydroxyl substitutions in the meta-
and para-positions on the aryl rings appear necessary for some measure of improved inhibitory activity. The best lead
inhibitors have either their meta- and para-substituted methoxyl and hydroxyl groups reversed from that of curcumin or
methoxyl or hydroxyl groups placed in both positions. The simple substitution of the para-hydroxy group on curcumin with
a methoxy substitution improved inhibitor function by 6-7-fold over that measured for curcumin.
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Introduction
It is estimated that approximately 20 million people worldwide
currently suffer from age-related dementia caused by Alzheimer’s
Disease (AD). Individuals afflicted with AD suffer from a variety of
unpredictable behaviors including loss in cognition, poor learning
and memory, and severe mood changes. The prevalence of the
pathology increases from 3% of the population at age 65 to 47%
after the age of 85 [1]. The neuropathology of AD has been well
studied over the past several decades. One of the earliest histological
changes seen in the brains of AD patients is the deposition of
amyloid-like plaques. The presence of amyloid plaques predisposes
clinical symptoms of cognitive impairment suggesting that these
abnormal brain deposits participate in events leading to the clinical
presentation of dementia [2,3,4]. Formation of these plaques is
thought to begin in the entorhinal complex and hippocampus, later
progressing into the neocortex [5]. Disease progression is accom-
panied by a decrease in neural metabolic activity and an increase in
neural cell death. These observations have led to the hypothesis that
a reduction in amyloid plaque burden is expected to slow or halt the
progression of AD and improve cognitive function.
Although many blood-borne proteins have been identified in
amyloid plaques, the main constituent is a hydrophobic peptide
called Ab [6]. The Ab peptide originates from what is believed to
be normal processing of the amyloid precursor protein (APP).
APP, a transmembrane protein, is cleaved in two successive
proteolytic reactions to release Ab peptide, which is either 40 or 42
amino acids in length depending on its intramembrane cleavage
site. Once formed, it is thought that Ab is cleared through normal
drainage function of the cerebral spinal fluid (CSF) [7,8,9]. Ab-
related pathologies develop when free peptide, once reaching a
critical concentration, forms insoluble oligomers which seed
further aggregation eventually leading to the formation of
characteristic amyloid lesions.
Current therapies for Alzheimer’s disease focus largely on
symptomatic aspects of the clinical pathology. Strategies include
increasing cholinergic neurotransmission by administering acetyl-
choline esterase inhibitors (e.g. Tacrine or Donepezil) [10] and
modulation of NMDA receptor activity by Memantine [11].
Although these therapies have shown a modest effect on slowing
cognitive decline, they have yet to demonstrate any major impact
on the progression of the disease. As an alternative to these
therapies, prevention of Ab aggregation has been attempted
through use of small molecule inhibitors [12,13]. From these
efforts, a number of useful lead compounds have been identified
such as sulfonated anions, benzofuran derivatives, as well as other
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usefulness of these inhibitors has been limited due to their toxicity
or their inability to cross the blood-brain barrier.
In contrast to these compounds, it was recently reported that the
natural product curcumin, a non-toxic component of the spice
turmeric, is capable of crossing the blood-brain barrier when
injected into the circulation and reduce amyloid plaque burden in
vivo in a transgenic mouse model [19,20]. Curcumin is also capable
of disaggregating preformed Ab fibrils [21,22]. Curcumin was less
effective, however, when added to the diet [23,24] indicating that
its effectiveness in vivo has considerable room for improvement.
Based upon its proven bioactive properties, it can be hypothesized
that curcumin presents molecular features that make it an
excellent lead compound for the development of more effective
inhibitors of Ab aggregation. Recently, investigators have begun to
address this hypothesis by introducing modifications into the basic
structure of curcumin and examining the effect of these changes on
Ab aggregation [25,26], neuroinflammation [25] and Ab-induced
neurotoxicity [27]. Results from these investigations have shown
that replacement of the 1,3-dicarbonyl moiety in curcumin with
isosteric isoxazoles and pyrazoles generated compounds that
inhibited g-secretase activity [28] and prevented both Ab and
Tau aggregation [26]. More modest changes in the curcumin
structure still retained protective activity toward Ab-induced
neurotoxicity [27]; however, some changes, such as saturation of
the 7-carbon linker to generate tetrahydrocurcumin, abolished Ab
aggregation inhibitory activity, but retained anti-neuroinflamma-
tion activity [25]. Although these findings clearly show that the
base structure of curcumin can be modified without compromising
certain properties of its bioactivity, none of the compounds tested
show significant improvement as Ab aggregation inhibitors when
compared to native curcumin. To further explore if modifications
to the native structure of curcumin can result in the identification
of improved inhibitors of Ab aggregation, we have generated
chemical analogs of curcumin with various modifications and
substitutions on the phenolic rings, varying degrees of unsaturation
of the spacer between between aromatic rings, as well as
compounds that contain either 5- or 7-carbon spacers to
determine if spatial variations between phenols affects anti-Ab
aggregation activity [29]. We have identified several novel analogs
of curcumin that are improved inhibitors of Ab oligomerization.
Materials and Methods
Reagents and Materials
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), dimethylsulfoxide
(DMSO), fraction V bovine serum albumin and all buffer reagents
were obtained from Sigma-Aldrich (St. Louis, MO). Tetramethyl-
benzidine (TMB) was purchased from Roche (Indianapolis, IN).
Human Ab(1–42) was purchased from AnaSpec (San Jose, CA).
NUNC MaxiSorp ELISA plates were obtained from eBioscience
(San Diego, CA). Monoclonal antibody 4G8 specific for human Ab
amino acids 17–24 and horseradish peroxidase (HRP)-conjugated
4G8 were purchased from Signet Labs (Dedham, MA). Synthesis of
curcumin and analogs was previously reported [29].
Preparation of monomeric Ab(1–42) peptide
Ab(1–42) peptide was dissolved in HFIP [30,31] to a final
concentration of 4 mg/ml and divided into 500 mg aliquots.
Aliquots were dried under a stream of sterile N2 and stored at
220uC until use. Immediately preceding each experiment,
aliquots were dissolved in DMSO to a final concentration of
1 mM. Solutions were sonicated for 15 min followed by heating at
60uC for an additional 15 min. Any unused peptide was discarded.
Aß peptide oligomerization reactions
Ab peptide from DMSO stock was diluted to the indicated
concentrations either into phosphate buffered saline, pH 7.2 (PBS)
alone or into test compound, pre-diluted into PBS. Stock solutions
of all test compounds were made with DMSO for solvent
compatibility. Dilutions were large enough to ensure that final
DMSO concentrations were consistently ,1% in the reaction mix.
Reactions were incubated at 37uC for 24 h and then processed for
capture ELISA.
Capture ELISA for Ab oligomer detection
NUNC Maxisorp high-binding ELISA plates were coated with
mAb 4G8 diluted to 2 mg/ml in PBS for a minimum of 16 h at
4uC. After rinsing plates with PBS and blocking non-specific sites
with PBS-T/B (PBS containing 0.1% Tween-20, 1% bovine
serum albumin) for 1.5 h, Ab peptide oligomerization reactions
were added to wells and incubated with immobilized capture mAb
for 2 h. Wells were rinsed three times with TBS-T (20 mM Tris-
HCl, 150 mM NaCl, pH 7.4, 0.05% Tween-20) using a Biotek
ELx50 automated plate washer. HRP-conjugated mAb 4G8 was
added to wells at 1 mg/ml diluted into PBS-T/B and incubated at
23uC for 1 h. Unbound secondary antibody was removed by
rinsing three times with TBS-T and bound antibody was measured
following addition of TMB reagent. TMB reaction was terminated
after ,10 min with the addition of an equal volume of 1 M
H2SO4. Absorbance was recorded at 450 nm with a reference
wavelength of 650 nm using a Molecular Devices SpectraMax 384
Plus plate reader.
Wst-1 assay
Microglial cells (100 ml containing 50,000 cells) were added to
wells of a 96-well culture plate and incubated for 24 h at 37uCi na
5% CO2 incubator. Cells were then incubated with the indicated
concentrations of curcumin or compound 2 and cells were
incubated for an additional 24 h. Media was removed and Wst-1
reagent (diluted 1:40 into complete phenol red-free media) was
added to each well and the cultures were incubated at 37uC, 5%
CO2 for 1 h. Absorbance was measured at 460 nm.
Statistical analyses
All experimental protocols were carried out in at least triplicate
points to determine mean values. Error bars represent standard
deviation from mean values. Intra- and inter-assay variations for
capture ELISAs were routinely #5%.
Results
We have previously constructed a chemical library of curcumin-
based analogs for the initial purpose of identifying the functional
groups responsible for curcumin’s anti-oxidant properties [29,32].
This library includes compounds with the following variations on
the curcumin structure. Some compounds have five carbon
spacers between the aromatic rings instead of the seven carbon
spacer of curcumin. The degree of unsaturation of the spacer is
varied. The positions and number of the phenolic and methoxyl
groups are varied and in some cases other groups are present.
Some compounds also have substitutions at the central carbon of
the spacer.
In order to perform large-scale screening of our analog library
in a rapid, reproducible and cost-effective manner, we developed a
novel ELISA-based assay to quantify oligomeric Ab peptide [33].
Importantly, this assay clearly distinguishes the oligomeric
conformation of the Ab aggregate from the fibrillar form, which
is important since the oligomeric form of Ab aggregates is
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synaptic dysfunction [34].
We first performed a general screen of our curcumin-based
chemical analog library to identify if compounds are present in our
library that are more effective than curcumin in preventing
formation of Ab oligomers. Analogs were tested for anti-Ab
aggregation activity at curcumin’s IC50 value (1 mM) for Ab
oligomerization. This IC50 value for curcumin was previously
established [33,35]. For analog screening, monomeric Ab peptide
(200 nM) was incubated alone or with 1 mM curcumin or with
1 mM of the indicated analog. Following this incubation, oligomers
were then quantified by capture ELISA. Analogs were identified
that inhibited Ab oligomerization equal to or better than curcumin
(Fig. 1; Inhibitory activity $50% within one S.D. of mean
values). A total of 20 compounds met this criteria and were used
for a structure/function assessment (Fig. 1). Structures of the 20
analogs are shown in Figure 2 and include 7 compounds from the
7-carbon series and 13 compounds from the 5-carbon series.
Interestingly, all of these curcumin analogs have unsaturated
linkers joining the phenolic rings, yet contain a variety of ring
substitutions which likely dictates the quantitative differences
measured in inhibitory function.
We next selected our three best compounds (compounds 1, 2,
and 8) for dose-response studies. Compounds 1 and 8 both
demonstrated anti-aggregation IC50 values slightly less than
curcumin, 0.8 mM and 0.6 mM, respectively (Fig. 3). Compound
2 demonstrated markedly improved inhibitory capacity over that
of curcumin with an IC50 value of 0.15 mM, making it the best
lead compound identified in this analog library.
Since curcumin has been reported to demonstrate cytotoxicity
in some cultured cell systems [36], we determined if our lead
compound 2 showed equal, or perhaps reduced, levels of toxicity
toward cells of neuronal origin. Murine microglial cells were
incubated with varying concentrations of either curcumin or
compound 2 for 24 hr and cell health was assessed by measuring
cytoplasmic dehydrogenase activity. Consistent with previous
results, curcumin demonstrated dose-dependent toxicity effects
with an LD50 value of 40 uM (Fig. 4). Compound 2 also showed
some toxicity toward microglial cells, however, its LD50 value is
approximately 2-fold lower than that of curcumin. This finding
shows that, in addition to improving on curcumin’s anti-
aggregation effects, compound 2 also shows reduced cytotoxicity
as compared with curcumin. Most importantly, the IC50 value of
compound 2 for anti-aggregation activity is well below its LD50
levels for cytotoxicity. This indicates that the dosage of compound
2 required for biologic activity is expected to be well below
concentrations that might induce neuronal cytotoxicity; an
important consideration to validate compound 2 as a viable lead
compound.
Discussion
Recent studies utilizing well established animal models have
provided valuable insights on curcumin’s role in AD [20,37].
Figure 1. Structure/function assessment of curcumin analogs. Quantitative assessment of 20 curcumin analogs for inhibitory activity of Ab
aggregation and comparison with chemical substitutions made to the curcumin structure.
doi:10.1371/journal.pone.0031869.g001
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Ab deposition in aged APP(Swedish)-transgenic mice (Tg2576)
demonstrating its ability to cross the blood-brain barrier in sufficient
quantities to reduce amyloid burden. In vitro measurements have
permitted a quantitative assessment of curcumin function by
showing that it inhibits the formation of low-molecular weight Ab
oligomers and high-molecular weight fibrils with IC50 values of
1.0 mM and 0.8 mM, respectively [20]. These observations, among
others, have helped to establish curcumin as one of the most
promising lead compounds in recent years that offers real potential
for reducing amyloid deposition in AD, and in doing so, halting or
reversing disease progression. The goal of the present study was to
identify and develop more effective aggregation inhibitors by
capitalizing on the newly established inhibitory properties of
curcumin. In order to achieve this goal, we have hypothesized that
the base structure of native curcumin provides an excellent starting
point to identify chemical analogs that have greater efficacy in
reducing or preventing Ab peptide oligomer formation, while
improving upon the generally poor bioavailability of curcumin.
The low micromolar IC50 value for inhibition of Ab
oligomerization clearly shows curcumin’s potent bioactivity both
in vitro and in vivo, and yet, this value also indicates that there is
much room for improvement. To identify improved inhibitors, we
have examined our previously constructed chemical library of
analogs [29] for inhibitors of Ab oligomerization that are
significantly improved over the bioactivity of curcumin. This
library includes compounds with variations on carbon spacer
length between phenolic rings (7- or 5-carbons in length), a variety
of ring substitutions, as well as substitutions to the central
methylene carbon of curcumin.
In general, our studies indicate that at least one enone group on
the spacer is necessary for measureable anti- Ab aggregation
activity. The most striking feature among compounds in both the
7- and 5-carbon series listed in Figure 1 is the presence of an a/b-
unsaturated carbon spacer. None of the compounds with saturated
spacers demonstrated inhibitory activity (data not shown),
indicating that an unsaturated spacer between aryl rings is
essential for anti- Ab aggregation activity. A similar finding was
Figure 2. Structures of active analogs of curcumin. The analogs shown were identified as those that inhibited Ab oligomerization equal to or
better than curcumin (data obtained from Figure 1; inhibitory activity $50% within one S.D. of mean values). These analogs include 7 compounds
from the 7-carbon series and 13 compounds from the 5-carbon series.
doi:10.1371/journal.pone.0031869.g002
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amyloidogenic activities of dietary curcumin with that of
tetrahydrocurcumin [25]. Further study of Figure 1 reveals novel
structure/function relationships with regard to specific substitu-
tions to the aryl rings. Ortho-substitutions do not appear to
contribute to improved inhibitor activity; however, maintaining
methoxyl and hydroxyl substitutions in the meta- and para-
positions on the aryl rings is necessary for comparable or improved
inhibitory activity when measured against curcumin. In the 5-
carbon series, one compound was significantly improved over that
of curcumin, compound 8, which has hydroxyl groups in both
meta- and para-positions of the aryl rings (Fig. 5). The most
improved inhibitors identified in the 7-carbon series have their
meta- and para-substituted methoxyl and hydroxyl groups
reversed from that of curcumin, as with compound 1, or methoxyl
groups placed in both positions, as with compound 2 (Fig. 5). The
simple substitution of the para-hydroxy group on curcumin with a
methoxy substitution (compound 2) improved inhibitor function
by 6-7-fold over that measured for curcumin, making compound 2
our most potent lead analog for anti-Ab aggregation activity.
Additional challenges lie ahead to improve the bioactivity of our
curcumin-derived analog in order to increase the therapeutic dose
to the CNS. Questions in regard to bioavailability have plagued
the use of curcumin as a potential therapeutic for a number of
years [23]. Clinical trials have shown that the inherent
bioavailability of orally administered curcumin is relatively low
when factoring in intestinal absorption, liver metabolism and BBB
penetrance [38]. However, in spite of these difficulties, dietary
supplementation of curcumin administered to aged APP(Swedish)-
transgenic mice (Tg2576) significantly lowered Ab deposition in
the CNS [20]. These findings clearly show that curcumin is able to
enter the circulation and cross the BBB in sufficient quantities to
reduce amyloid burden. To improve upon this property, we
anticipate that the methoxy substitution on our lead compound 2
will decrease polarity and increase lipid membrane solubility
thereby improving passive diffusion across the blood brain barrier
(BBB) and access to the CNS [39,40]. Similar observations have
been made for other inhibitors of Ab aggregation such as
Chrysamine G [41]. In this study, the more lipophilic compound
Chrysamine G was compared with Congo Red and found to
readily cross the BBB in normal mice, achieving a brain:blood
ratio of greater than 10:1. Moreover, metabolic inactivation poses
other challenges to maintaining bioactivity. In this respect, the
hydroxyl groups on curcumin are modified by enzymes found in
the liver, kidney and intestinal mucosa [42] to form curcumin
glucuronides and curcumin sulfates [43,44]. The methoxy
substitution for these hydroxyl groups on our lead compound 2
should prevent these glucuronide and sulfate additions and
contribute to sustained bioactivity.
Proceeding from successful transgenic mouse studies
[19,22,25,45], human clinical trials have recently been initiated
that are designed to examine the efficacy of dietary curcumin in
slowing or reversing cognitive decline [46]. In general, curcumin
studies have demonstrated that dietary administration of the
compound in doses up to 12 g per day is well tolerated [46];
however, its effects on slowing or reversing cognitive decline have
been modest at best and very often dependent on the stage of AD
when treatment commences. For example, in an Asian study of
1,010 non-demented individuals, a small but statistically significant
improvement in cognitive abilities was noted in a population that
consumed curry more than once per month [47]. By contrast, in a
more recent six-month randomized study, patients with moderate-
to-severe Alzheimer’s disease showed little or no measureable
improvement when compared with placebo controls [48]. These
clinical findings conflict with data obtained from curcumin-treated
animal models and suggest challenges lie ahead in translating
findings from rodent studies to human trials. Perhaps these
challenges can be met by more clearly defining the objective of
curcumin treatment; either as a preventative to delay or avert the
onset of significant cognitive impairment in early stage AD
patients or as a therapeutic aimed at reversing the clinical
hallmarks of dementia found in more advanced stages. Thus far,
Figure 4. Quantitative assessment of cytotoxic effects of
curcumin and compound 2 on murine microglial cells. Cultured
microglial cells were incubate without or with the indicated concen-
trations of curcumin or compound 2 for 24 h. Cells were then incubated
with Wst-1 reagent for 1 h, afterwhich absorbance was measured
(460 nm). Values on graph represent mean values calculated from
triplicate experimental points. Standard deviations from mean values
were determined as ,5% for each experimental point.
doi:10.1371/journal.pone.0031869.g004
Figure 3. Quantitative comparison of curcumin with analogs 1,
2, and 8a sA b oligomerization inhibitors. Soluble Ab monomeric
peptide was prepared as described in methods and diluted to a final
concentration of 200 nM directly into phosphate buffered saline (PBS),
pH 7.4, or PBS containing the indicated concentrations of curcumin or
analogs 1, 2 or 8. Reactions were incubated at 37uC for 24 h. Oligomers
were quantified by capture ELISA. All reactions were prepared in
triplicate to calculate mean values. Standard deviations from mean
values were calculated and amounted to ,5% for each experimental
point.
doi:10.1371/journal.pone.0031869.g003
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administering curcumin to animals prior to their developing AD
pathologies, whereas the majority of human trials that have been
attempted largely recruit individuals who are already symptomatic
of AD and likely to have significant amyloid plaque burden.
Reversing an already substantial plaque load may require multiple
therapeutic modalities to supplement curcumin’s bioactivity [49]
or, alternatively, a more effective compound targeting Ab plaque
development such as the improved inhibitor presented here.
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